Ortho-McNeil Adds Axert To Pain Portfolio; Pfizer Left With One Triptan
Executive Summary
Ortho-McNeil will enter the triptan migraine class by taking over Pharmacia's marketing rights to Axert
You may also be interested in...
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg
Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg